Licence VPA10996-105-001 27042018145720

Health Products Regulatory Authority
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Cobactan LC, 75 mg, intramammary ointment for lactating cattle
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each prefilled syringe of 8g contains:

Active substance:

Cefquinome 75 mg (as cefquinome sulphate)

Excipients:

For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
White to slightly yellow, oily viscous homogeneous intramammary ointment.
4 CLINICAL PARTICULARS
4.1 Target Species
Lactating cows.
4.2 Indications for use, specifying the target species
For the treatment of clinical mastitis in the lactating dairy cow caused by the
following cefquinome-sensitive organisms : Streptococcus uberis, Streptococcus
dysgalactiae, Staphylococcus aureus and Escherichia coli.
4.3 Contraindications
Not to be administered to animals which are known to be hypersensitive to

cephalosporin antibiotics and other ß-lactam antibiotics.
Do not use the cleaning towel if lesions are present on the teat.
4.4 Special warnings for each target species
None.
27 April 2018 CRN000XTC Page 1 of 5

4.5 Special precautions for use
Special precautions for use in animals
Use of the product should be based on susceptibility testing and take into account
official and local antimicrobial policies. Inappropriate use of the product may
increase the prevalence of bacteria resistant to cefquinome and may decrease the
effectiveness of treatment with cephalosporins, due to the potential for
cross-resistance.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection,
inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross
sensitivity to cephalosporin and vice versa. Allergic reactions to these substances
may occasionally be serious.
1. Handle this product with great care to avoid exposure, taking all recommended
precautions.
2. Do not handle this product if you know you are sensitive to such preparations, or if
you have been advised not to work with them.
3. If you develop symptoms following exposure, such as a skin rash, you should seek
medical advice and show the Doctor this warning. Swelling of the face, lips and eyes
or difficulty in breathing are more serious symptoms and require urgent medical
attention.
Wash hands after using the cleaning towels and wear protective gloves if skin
irritation due to Isopropyl alcohol is known or suspected.
4.6 Adverse reactions (frequency and seriousness)
In very rare cases anaphylactic reactions have been noted in animals after
administration of the product.

The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
4.7 Use during pregnancy, lactation or lay
The product is intended for use during lactation. There is no available information
indicating reproductive toxicity (inc. teratogenicity) in cattle. In reproductive toxicity
studies in laboratory animals cefquinome did not reveal any effect on reproduction
or teratogenic potential.

4.8 Interaction with other medicinal products and other forms of interaction
It is known that a cross sensitivity to cephalosporins exists for bacteria sensitive to

the cephalosporin group.
4.9 Amounts to be administered and administration route
The contents of one syringe should be infused gently into the teat of the infected
quarter every 12 hours after each of three successive milkings.
Milk out the affected quarter(s). After thoroughly cleaning and disinfecting the teat
and teat orifice with the cleaning towel provided, gently infuse the contents of one
syringe into each affected quarter. Disperse the product by gentle massage of the
teat and udder of the affected animal.
The syringe must only be used once. Partly used syringes should be discarded.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
No symptoms expected or emergency procedures required.
4.11 Withdrawal period(s)
Meat and offal:4 days

Milk: 5 days (120 hours).
5 PHARMACOLOGICAL or IMMUNOLOGICAL PROPERTIES
Pharmacotherapeutic group: Antibacterials for intramammary use, fourth-generation

cephalosporins.

ATC vet code: QJ51DE90.
5.1 Pharmacodynamic properties
Cefquinome is an antibacterial drug of the cephalosporin group which acts by

inhibition of cell wall synthesis. It is characterised by its broad therapeutic spectrum
of activity and a high stability against beta-lactamases.

In vitro, Cefquinome has antibiotic activity against common Gram negative and Gram
positive bacteria including Escherichia coli, Staphylococcus aureus, Streptococcus
dysgalactiae, Streptococcus agalactiae and Streptococcus uberis.

As a fourth generation cephalosporin, cefquinome combines high cellular
penetration and a high beta-lactamases stability. In contrast to cephalosporins of
previous generations, cefquinome is not hydrolysed by chromosomally–encoded
cephalosporinases of the Amp-C type or by plasmid mediated cephalosporinases of

some enterobacterial species. Resistance mechanism in Gram negative organisms

due to extended spectrum beta-lactamases (ESBL) and in Gram-positive organisms
due to alteration of penicillin binding proteins (PBPs) may lead to cross-resistance
with other beta-lactams.
5.2 Pharmacokinetic particulars
After intramammary administration, a mean concentration of 19 mcg/ml in milk is

observed 12 hours post last infusion. The highest MIC 90 value was found for
Staphylococcus aureus. This pathogen has a MIC90 in the range of 1 mcg/ml.

At the second milking following the last infusion the mean concentration is still
approximately 2.5 mcg/ml and then falls to 0.75 mcg/ml at the third milking post last
infusion.

Resorption of cefquinome from the udder is insignificant.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
White soft paraffin

Liquid paraffin
6.2 Major incompatibilities
None known.
6.3 Shelf-life
Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
6.4 Special precautions for storage
Do not store above 25°C.
6.5 Nature and composition of immediate packaging
White opaque polyethylene syringes and cleaning towels in paper aluminium

copolymer laminate sachet.
Packs of 3, 15, 20 and 24 syringes and cleaning towels.
Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal

products or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such
veterinary medicinal products should be disposed of in accordance with local
requirements.
7 MARKETING AUTHORISATION HOLDER
Intervet Ireland Limited

Magna Drive
Magna Business Park, Citywest Road
Dublin 24
Ireland
8 MARKETING AUTHORISATION NUMBER(S)
VPA 10996/105/001
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Date of first authorisation: 14/05/1998

Date of last renewal: 28/05/2009
10 DATE OF REVISION OF THE TEXT
April 2018

Licence VPA10996-105-001 27042018145720

Uploaded by

Copyright:

Available Formats

Licence VPA10996-105-001 27042018145720

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Licence VPA10996-105-001 27042018145720

Uploaded by

Copyright:

Available Formats

Health Products Regulatory Authority

1 NAME OF THE VETERINARY MEDICINAL PRODUCT

Cobactan LC, 75 mg, intramammary ointment for lactating cattle

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each prefilled syringe of 8g contains:

White to slightly yellow, oily viscous homogeneous intramammary ointment.

4.1 Target Species

4.2 Indications for use, specifying the target species

Not to be administered to animals which are known to be hypersensitive to

4.4 Special warnings for each target species

27 April 2018 CRN000XTC Page 1 of 5

4.5 Special precautions for use

4.6 Adverse reactions (frequency and seriousness)

4.7 Use during pregnancy, lactation or lay

27 April 2018 CRN000XTC Page 2 of 5

It is known that a cross sensitivity to cephalosporins exists for bacteria sensitive to

4.9 Amounts to be administered and administration route

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

No symptoms expected or emergency procedures required.

4.11 Withdrawal period(s)

Meat and offal:4 days

5 PHARMACOLOGICAL or IMMUNOLOGICAL PROPERTIES

Pharmacotherapeutic group: Antibacterials for intramammary use, fourth-generation

5.1 Pharmacodynamic properties

Cefquinome is an antibacterial drug of the cephalosporin group which acts by

27 April 2018 CRN000XTC Page 3 of 5

some enterobacterial species. Resistance mechanism in Gram negative organisms

5.2 Pharmacokinetic particulars

After intramammary administration, a mean concentration of 19 mcg/ml in milk is

6.1 List of excipients

White soft paraffin

6.2 Major incompatibilities

6.4 Special precautions for storage

Do not store above 25°C.

6.5 Nature and composition of immediate packaging

White opaque polyethylene syringes and cleaning towels in paper aluminium

27 April 2018 CRN000XTC Page 4 of 5

6.6 Special precautions for the disposal of unused veterinary medicinal

7 MARKETING AUTHORISATION HOLDER

Intervet Ireland Limited

8 MARKETING AUTHORISATION NUMBER(S)

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 14/05/1998

10 DATE OF REVISION OF THE TEXT

27 April 2018 CRN000XTC Page 5 of 5

You might also like